115 related articles for article (PubMed ID: 20667889)
1. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.
Brüggemann RJ; van Luin M; Colbers EP; van den Dungen MW; Pharo C; Schouwenberg BJ; Burger DM
J Antimicrob Chemother; 2010 Oct; 65(10):2188-94. PubMed ID: 20667889
[TBL] [Abstract][Full Text] [Related]
2. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
3. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.
Jacobs BS; Colbers AP; Velthoven-Graafland K; Schouwenberg BJ; Burger DM
Int J Antimicrob Agents; 2014 Aug; 44(2):173-7. PubMed ID: 24929949
[TBL] [Abstract][Full Text] [Related]
4. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
van der Lee MJ; Blenke AA; Rongen GA; Verwey-van Wissen CP; Koopmans PP; Pharo C; Burger DM
Antimicrob Agents Chemother; 2007 Nov; 51(11):4098-104. PubMed ID: 17846135
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
[TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
9. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
[TBL] [Abstract][Full Text] [Related]
10. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Pérez-Elías MJ; Morellon ML; Ortega E; Hernández-Quero J; Rodríguez-Torres M; Clotet B; Felizarta F; Gutiérrez F; Pineda JA; Nichols G; Lou Y; Wire MB
Antimicrob Agents Chemother; 2009 Dec; 53(12):5185-96. PubMed ID: 19667283
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
[TBL] [Abstract][Full Text] [Related]
14. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
[TBL] [Abstract][Full Text] [Related]
15. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Wire MB; Shelton MJ; Studenberg S
Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
[TBL] [Abstract][Full Text] [Related]
16. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
[TBL] [Abstract][Full Text] [Related]
17. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.
Kiser JJ; Lichtenstein KA; Anderson PL; Fletcher CV
Pharmacotherapy; 2006 Apr; 26(4):511-4. PubMed ID: 16553510
[TBL] [Abstract][Full Text] [Related]
18. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
Gruber VA; Rainey PM; Moody DE; Morse GD; Ma Q; Prathikanti S; Pade PA; Alvanzo AA; McCance-Katz EF
Clin Infect Dis; 2012 Feb; 54(3):414-23. PubMed ID: 22100576
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
Pellegrin I; Breilh D; Coureau G; Boucher S; Neau D; Merel P; Lacoste D; Fleury H; Saux MC; Pellegrin JL; Lazaro E; Dabis F; Thiébaut R;
Antimicrob Agents Chemother; 2007 Apr; 51(4):1473-80. PubMed ID: 17296739
[TBL] [Abstract][Full Text] [Related]
20. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
Wire MB; Baker KL; Jones LS; Shelton MJ; Lou Y; Thomas GJ; Berrey MM
Antimicrob Agents Chemother; 2006 Apr; 50(4):1578-80. PubMed ID: 16569890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]